Avon unveils a bio-printed menopausal skin model to advance menopause-focused skincare research.

Avon's 3D bio-printed menopausal skin model is a breakthrough in femtech and cruelty-free testing. It has been developed with cells from Brazilian women in a controlled hormonal environment and also replicates menopausal conditions like collagen loss and increased sensitivity to study skin changes, all without using animal testing.
This innovative model is used for animal-free cosmetic testing and product development, aiming to improve the precision of skincare formulations targeted at menopausal consumers.

According to Towards Healthcare, the Latin America bioregenerative aesthetic injectable market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 260.83 million in 2026 to approximately USD 834.91 million by 2035, representing a compound annual growth rate (CAGR) of 13.8% from 2026 to 2035. Growth is driven by patients who are increasingly desiring natural-looking, long-lasting anti-aging results with minimal downtime and biologically driven therapies, which include polynucleotides (PN) and exosome-based injectables that are gaining rapid growth for deep cellular repair and superior skin quality.

About Avon

Avon has collaborated with Natura, which is the parent company and pioneer in 3D bioprinting across Latin America, to develop the world's first human skin tissue for menopause conditions.

With Avon’s product innovation strategy, which focuses on potent and home topical bioregenerative technologies, the company provides serums and creams that mimic the plumping and hydrating effects of clinical injectables.

Eduardo Marques, CCO VML Brazil, said, "The company has broken the barrier between laboratory and communication. If technology were capable of bioprinting a menopausal skin to care for women, our main mission was to transform that achievement into a manifesto that honours the female journey. Science and creativity are not separate languages; they're the same language but spoken differently."

Skin research manager, Luciana Vasquez, stated that "A key distinguishing feature of this research is the use of cells sourced from Brazilian women, providing a more representative and accurate model of the target population. The model was placed in a controlled hormonal environment with lower estrogen and progesterone levels, the primary drivers of the skin alterations observed during this phase. The 3D bioprinted skin technology offers exceptional precision, enabling the development and evaluation of formulations with unprecedented accuracy."

A recent report by Towards Healthcare highlights that the Latin America bioregenerative aesthetic injectable market is witnessing growth due to the increasing demand from men and the younger customer segment who use bioregenerative injectables as proactive, preventative anti-aging measures rather than corrective treatments. The growing popularity of bioregenerative injectables among men and younger age groups reflects a shift towards preventive and long-term antiaging care.